Sign in

NCT06762925Not yet recruiting

Study on the Efficacy and Mechanism of METTL3 Peptide Inhibitors in Enhancing Anti-tumor Immune Response by Reshaping the Tumor Microenvironment

Source: ClinicalTrials.gov · Last updated 8 Jan 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

This study aims to validate the accuracy and clinical value of METTL3 as a biomarker for predicting immune therapy response in patients with urinary tract tumors through observational studies.

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
450 (estimated)
First submitted
21 Nov 2024
Start date
30 Jan 2025
Primary completion date
1 Jun 2026
Lead sponsor
Xijing Hospital
NCT number
NCT06762925

What you commit to

  • Study type: Observational
  • Planned participants: 450
  • From 30 Jan 2025 to the primary completion date, 1 Jun 2026
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Not meeting the specific clinical stage and not receiving surgical treatment;

Age

  • Age under 18 years old or over 75 years old;

Other

  • Abnormal mental behavior;
  • Intellectual disability;
  • Low understanding and communication skills.

Who the study is looking for

  • Patients diagnosed with urinary system tumors through pathological examination;
  • Meet specific clinical stages and surgical treatment standards;
  • Intraoperative tissue resection meets the sample testing standards;
  • The patient is willing to participate in the study and sign an informed consent form.

Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.